At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 212 enrolled
Drug / intervention
Pemvidutide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Pemvidutide in Non-Cirrhotic Subjects With Nonalcoholic Steatohepatitis (NASH)
In Brief
A Phase 2 clinical trial evaluating Pemvidutide and Placebo for Non-Alcoholic Steatohepatitis (NASH). Completed, enrolled 212 participants across 40 sites in 3 countries.
Detailed Summary
Purpose of this study is to assess the effects of pemvidutide on NASH resolution and NASH fibrosis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Alcoholic Steatohepatitis (NASH)
CountriesAustralia, Puerto Rico, United States
Collaborators--
Timeline
Phase 2CompletedFinished
202420252026
Enrollment StartJul 2023
First PostedAug 2023
Primary CompletionNov 2025
TodayJul 2026
First PostedAug 14, 2023
Enrollment StartJul 27, 2023
Primary CompletionNov 25, 2025
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 2.9 years ago
Interventions
Pemvidutidedrug
Administered once weekly by subcutaneous injection
Placebodrug
Administered once weekly by subcutaneous injection